Tradestie Institutional Equity Comparison Engine

MDEV vs FTXH โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

FTXH Overall Edge

FTXH Captures Institutional Edge (2โ€“0 Pillars ยท 3โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to First Trust Nasdaq Pharmaceuticals ETF (FTXH) driven by superior Momentum & Technical, Options & Structure. Fundamentally, MDEV trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus FTXH at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, MDEV sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against FTXH sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
MDEV N/M vs FTXH N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner FTXH
1Y +10.2% vs +39.2% ยท 52W Pos 86% vs 91%
Options & Structure Winner FTXH
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (50th %ile IV)
MDEV Cboe BZX
First Trust Indxx Medical Devices ETF
Institutional Equity
$22.56
-0.33% 1D
Market Cap N/A
1M Return +5.76%
1Y Return +10.17%
Forward P/E N/M
Unified AI Score
41.2 / 100 SELL
Tech 31.0 Fund 43.0 Flow 50.0 Mom 50.0
FTXH NASDAQ
First Trust Nasdaq Pharmaceuticals ETF
Institutional Equity
$43.87
-0.81% 1D
Market Cap N/A
1M Return +5.3%
1Y Return +39.25%
Forward P/E N/M
Unified AI Score
50.1 / 100 HOLD
Tech 43.0 Fund 45.0 Flow 50.0 Mom 41.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MDEV +10.17% FTXH +39.25% Spread: +30.9 pp (FTXH Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MDEV TTM Op. Margin: N/A FTXH TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDEV vs FTXH. Trailing 12-month operating profitability (MDEV N/A vs FTXH N/A) and valuation multiples (MDEV N/M vs FTXH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MDEV (0) vs FTXH (3)
Institutional Metric MDEV FTXH Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 86% ($18โ€“$23) 91% ($31โ€“$45) Stronger Trend FTXH
Beta / 30D Volatility Risk Regime 0.55ฮฒ ยท 25% Vol 0.46ฮฒ ยท 22% Vol Lower Realized Risk FTXH
Unified Institutional Score Composite Signal 41.2 / 100 (SELL) 50.1 / 100 (HOLD) Higher Composite FTXH

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MDEV vs FTXH Buy Guide
MDEV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MDEV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FTXH UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live FTXH Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MDEV nor FTXH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.